nature portfolio

Corresponding author(s):	Jurgen Denecke
Last updated by author(s):	Feb 2, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

~ .			
St	at	ıctı	CS

For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a	Confirmed		
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
	A stateme	nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.		
\boxtimes	A description of all covariates tested		
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>		
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated		
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.	
So	ftware and	d code	
Poli	cy information a	about <u>availability of computer code</u>	
Da	ata collection	Zen 2.3 black edition (Zeiss)	
Da	ata analysis	Zen 2.3 lite blue edition (Zeiss) and ImageJ ((http://rsb.info.gov/ii/)).Image analysis was undertaken using the ImageJ analysis	

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets

programand the PSC co-localization plug-in

- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

This project has generated a large number of raw data that require standard manipulations such as subtracting a blank OD, calculating enzyme activities, calculating ratios between medium and cell samples, calculating averages, standard deviations and standard errors, all of which can be made available by the Lead contact upon reasonable request. For Figure 2A, the raw data for cells and medium, as well as the calculation of the secretion index can be found in the Source Data. Individual averages from separate biological replicas for Figures 3B, 3F, 5B, 5E, 6C, 7D and Supplementary Figures 3A, 3B, 3C, 6A, 6B, are included in Source Data. Uncropped gel images, blots, autoradiographs and FRAP data (Figures 1, 4A, 7 and Supplementary Figure 4A) can also be found in Source Data. Source data are provided with this paper.

ŀ	Human	research	particii	pants
ı	Tarriari	1 CJCarci	partici	Duile

Policy information :	about <u>studies i</u>	involving human research participants and Sex and Gender in Research.
Reporting on sex	and gender	N/A
Population chara	cteristics	N/A
Recruitment		N/A
Ethics oversight		N/A
_	ition on the appi	roval of the study protocol must also be provided in the manuscript.
Field-spe	ecific re	eporting
		is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
X Life sciences	E	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of t	he document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scier	nces sti	udy design
All studies must dis	close on these	points even when the disclosure is negative.
Sample size	Typical sample size was two to three million protoplasts in volumes of 2-2.5 mL cell suspensions for all transport experiments to minimise pipetting errors and artefacts such as protoplasts adhering to petri-dish surface.	
Data exclusions	No data were	e excluded.
Replication	We use a combination of repeats with dose response assays and can illustrate reproducibility visually in our graphs. The source data can be consulted for further details.	
Randomization	Not Applicable as the experiments were performed on millions of cells.	
Blinding	Co-localisation studies were performed by a colour-blind investigator to avoid sample bias.	
Behaviou	ıral & s	social sciences study design
All studies must dis	close on these	points even when the disclosure is negative.
Study description	N/A	
Research sample	nple N/A	
Sampling strategy	ing strategy N/A	

Data collection	N/A
Timing	N/A
Data exclusions	N/A
Non-participation	N/A
Randomization	N/A
Ecological, e	volutionary & environmental sciences study design
All studies must disclose or	n these points even when the disclosure is negative.
Study description	N/A
Research sample	N/A
Sampling strategy	N/A
Data collection	N/A
Timing and spatial scale	N/A
Data exclusions	N/A
Reproducibility	N/A
Randomization	N/A
Blinding	N/A

Reporting for specific materials, systems and methods

No No

Did the study involve field work?

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods		
n/a Involved in the study		n/a Involved in the study		
Antibodies		ChIP-seq		
Eukaryotic cell lines		Flow cytometry		
Palaeontology and a	rchaeology	MRI-based neuroimaging		
Animals and other o	rganisms			
Clinical data				
Dual use research of	concern			
ı				
Antibodies				
ago. anti-HA epitope (cat # GTX1)		clonal anti serum from rabbit, a kind gift by Birte Svensson (Carlsberg Laboratory, Copenhagen, Denmark) over two decades 104, Genetex); anti-GM130 (cat # 610822; clone 35/GM130; BD Biosciences), anti-TGN46 (cat # AHP500; Bio-Rad),Donkey ocat # A3157-1) and Donkey anti-sheep Alexa Fluor594 (Thermo cat # A11016)		
Validation	, , , , , , , , , , , , , , , , , , ,	ti-barley alpha amylase is described in Phillipson et al. (2001) and cited. other antibodies are heavily commercialised, validated and readily available for purchase		
Eukaryotic cell lin	es			
Policy information about <u>ce</u>	Il lines and Sex and Gender	<u>in Research</u>		
Cell line source(s) HeLa CCL-2 ce		vere purchased from the American Type Culture Collection (Manassas, VA).		
Authentication Please refer to Am		rican Type Culture Collection website for further information.		
Mycoplasma contamination Negative tests co		irmed.		
Commonly misidentified lines (See ICLAC register)				